What is your approach to patients who develop ARIA-E or ARIA-H during treatment with anti-amyloid therapies?  

We follow the published guidelines and the prescription information. We take into consideration the presence and severity of symptoms and ARIA severity on brain MRI.

We follow the recommendations in the drug label that depends on the severity of each ARIA (mild/moderate/severe). Depending on the severity of ARIA, treatment may be held pending follow-up evaluation or discontinued entirely.